Geode Capital Management LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,810,526 shares of the company’s stock after purchasing an additional 22,609 shares during the quarter. Geode Capital Management LLC’s holdings in Apellis Pharmaceuticals were worth $52,229,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its stake in Apellis Pharmaceuticals by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock worth $13,242,000 after buying an additional 22,273 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Apellis Pharmaceuticals by 15.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,614 shares of the company’s stock valued at $752,000 after purchasing an additional 2,635 shares in the last quarter. Panagora Asset Management Inc. acquired a new stake in Apellis Pharmaceuticals during the 2nd quarter valued at $907,000. Peregrine Capital Management LLC boosted its stake in Apellis Pharmaceuticals by 23.3% in the second quarter. Peregrine Capital Management LLC now owns 114,279 shares of the company’s stock worth $4,384,000 after purchasing an additional 21,619 shares in the last quarter. Finally, nVerses Capital LLC grew its holdings in shares of Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the last quarter. 96.29% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on APLS shares. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Needham & Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. William Blair started coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $25.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, November 4th. Finally, Piper Sandler decreased their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.94.
Apellis Pharmaceuticals Price Performance
Shares of APLS opened at $33.21 on Monday. The stock has a market cap of $4.13 billion, a P/E ratio of -16.36 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $73.80. The stock’s 50-day moving average price is $30.31 and its two-hundred day moving average price is $34.49. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the business earned ($1.17) EPS. The firm’s revenue was up 78.3% compared to the same quarter last year. On average, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Featured Stories
- Five stocks we like better than Apellis Pharmaceuticals
- What is a Bond Market Holiday? How to Invest and Trade
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- What Investors Need to Know About Upcoming IPOs
- CarMax Gets in Gear: Is Now the Time to Buy?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.